Health Care·Biotechnology·$26.7B
BioNTech SE is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. As a key player in the healthcare sector, its innovative approaches, particularly in mRNA technology, have gained significant attention, especially following the COVID-19 pandemic.
Earnings Per Share (EPS)
EPS is a critical measure of a company's profitability and will indicate how well BioNTech is managing its costs and revenue.
Revenue
Revenue figures will provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
-1.64%
Avg Stock Reaction
-3.52%
In Q4 2025, BioNTech reported an EPS of $-0.38, which was significantly worse than expected, leading to a sharp decline in stock price. The company did not provide revenue figures for the quarter.
Management Promises & Guidance
Analysts expect BioNTech to report a loss in the upcoming quarter, with a consensus EPS of $-1.91 and revenue of $159 million. The market is cautious due to previous earnings misses.
Bull Case
If BioNTech can exceed revenue expectations and show progress in its pipeline, it may signal a recovery in investor confidence and lead to a positive stock reaction.
Bear Case
Continued losses and disappointing revenue could reinforce concerns about the company's financial health and lead to further stock declines.
Earnings Per Share (EPS)
$-1.91EPS is a critical measure of a company's profitability and will indicate how well BioNTech is managing its costs and revenue.
Revenue
$159MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will BioNTech's revenue meet or exceed the consensus estimate of $159 million?
Revenue performance is crucial for assessing the company's market demand and financial stability, especially after recent misses.
Q2
What specific advancements can BioNTech report regarding its pipeline candidates?
Progress in its drug development pipeline could significantly impact investor sentiment and future revenue potential.
Why consensus could be wrong
The consensus may underestimate BioNTech's potential for revenue recovery due to new partnerships and advancements in its pipeline.
Supporting Evidence
Recent developments in mRNA technology could lead to unexpected revenue streams.
BioNTech's focus on cost management may result in better-than-expected EPS despite revenue challenges.
Key Risk
If revenue comes in above $159 million, it could challenge the current bearish outlook.
Pre-commit to what would confirm each case.
The upcoming earnings report is critical as it will reveal how well BioNTech is navigating its post-COVID landscape and managing its product pipeline.
Bull Confirmed If
Reporting revenue above $159 million and demonstrating progress in pipeline candidates would confirm the bull case.
Bear Confirmed If
Falling short of the $159 million revenue target and continued losses would solidify the bear case.
Implied Move
±4.2%
The options market is pricing in a moderate move for BioNTech's stock following the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If BioNTech beats expectations, history suggests a potential stock increase of around 2.5%, confirming a recovery narrative.
In-Line / Cautious
An in-line report could lead to muted reactions, as investors weigh management's commentary on future prospects.
Miss
A miss could result in a decline of approximately 5.4%, reinforcing bearish sentiment around the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026